We would like to thank again all the participating families who have contributed their clinical details to the PALB2 study over the years as without your help and support our study would not have been possible.
We started 10 years ago
In 2009, we established a consortium of clinicians, epidemiologists and researchers to work on PALB2 (the PALB2 Interest Group, PALB2-IG). We now have ~200 members and to date have held several meetings, with more recent one held in Vancouver. Our key activities are: refining penetrance, risks for other cancers, risk prediction models, functional work, pathology.
48 groups are contributing families now. Over 800 families/patients have been consented directly or via relatives, most have only one PALB2 mutation carrier.
What are the future plans?
We are now analysing the data to estimate breast cancer risks, ovarian ca, male breast ca, pancreas, prostate and all other cancers combined. We hope to publish our findings in 2019.
In the meantime the PALB2 Interest Group will continue its active recruitment alongside providing comprehensive information and support for the families and patients.
If you are interested in taking part please contact us. Thank you for your continuing support.